Build status - In Progress

A Multiple-Site Phase 1/2 Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

A Multiple-Site Phase 1/2 Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Recruiting
99 years or below
All
Phase 2
10 participants needed
1 Location

Brief description of study

Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 50% are caused by mutations in the cone-specific cyclic nucleotide gated channel beta subunit (CNGB3) gene.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Achromatopsia,inhertited retinal disorder,Eye disorder,reduced vision
  • Age: 99 years or below
  • Gender: All


Updated on 04 Aug 2024. Study ID: 842816

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center